15.85

9.06% -1.58

After Hours: 13.65 -2.20 -13.88%

Promis Neurosciences Inc (PMN)

Overview News Price History Financials Discussions Forecast Stock Split

Promis Neurosciences Inc stock is traded at $15.85, with a volume of 21,590. It is down -9.06% in the last 24 hours and down -20.19% over the past month. ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Previous Close:

$17.43

Open:

$17.44

24h Volume:

21,590

Relative Volume:

0.13

Market Cap:

$142.14M

Revenue:

Net Income/Loss:

$-29.28M

P/E Ratio:

-1.1673

EPS:

-13.5784

Net Cash Flow:

$-27.36M

1W Performance:

-6.76%

1M Performance:

-20.19%

6M Performance:

+58.90%

1Y Performance:

-4.37%

1-Day Range:

$15.85

$18.00

1-Week Range:

$15.85

$19.00

52-Week Range:

$6.27

$39.75

Promis Neurosciences Inc Stock (PMN) Company Profile

Name

Promis Neurosciences Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

416-847-6898

Address

SUITE 200, 1920 YONGE STREET, TORONTO

Employee

Twitter

Next Earnings Date

2026-03-30

Latest SEC Filings

PMN's Discussions on Twitter

Compare PMN vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PMN Promis Neurosciences Inc	15.85	156.31M	0	-29.28M	-27.36M	-13.58
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Promis Neurosciences Inc Stock (PMN) Latest News

01:03 AM

ProMIS Neurosciences 2025 Annual Report: Pipeline, Risks, and Strategic Objectives for Alzheimer’s Drug Development - Minichart

01:03 AM

Mar 25, 2026

ProMIS Neurosciences (PMN) files $50M at-the-market sales supplement - Stock Titan

Mar 25, 2026

ProMIS Neurosciences 10-K: $0 Revenue, ($22.61) EPS, Net Loss $39.72M - TradingView

Mar 25, 2026

Alzheimer’s antibody lead and ALS programs at ProMIS (NASDAQ: PMN) - Stock Titan

Mar 25, 2026

ProMIS Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Mar 25, 2026

ProMIS Neurosciences reports $39.7M net loss for FY2025, cash $6.1M; raises $75.5M in Feb 2026 - TradingView

Mar 25, 2026

Heavy 2025 loss but big AD bet for ProMIS Neurosciences (PMN) with $175M funding - Stock Titan

Mar 25, 2026

Alzheimer's drug trial enrolls 144 patients with no serious side effects - Stock Titan

Mar 25, 2026

Mar 23, 2026

Promis Neurosciences (PMN) to Release Earnings on Monday - Defense World

Mar 23, 2026

Mar 22, 2026

How does ProMIS Neurosciences Inc perform in inflationary periods2026 Technicals & Reliable Price Breakout Alerts - baoquankhu1.vn

Mar 22, 2026

If You Invested $1,000 in Promis Neuroscie (PMN) - Stock Titan

Mar 22, 2026

Mar 20, 2026

Activity Recap: How cyclical is ProMIS Neurosciences Incs revenue streamDollar Strength & Free Daily Entry Point Trade Alerts - baoquankhu1.vn

Mar 20, 2026

Mar 18, 2026

ProMIS Neurosciences (PMN) registers 13.83M shares after $75.5M private placement - Stock Titan

Mar 18, 2026

Wellington holds 9.99% of ProMIS Neurosciences (NASDAQ: PMN) via shares and warrants - Stock Titan

Mar 18, 2026

ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™) - Toronto Star

Mar 18, 2026

Mar 17, 2026